Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd has positioned itself uniquely in the regenerative and aesthetic medicine market through strategic partnerships, including an expanded agreement with STEMCELL Technologies, which enhances the supply chain for its rhCollagen product and bolsters North American growth opportunities. The company's advancements in 3D bioprinting, particularly with Collink.3D, demonstrated superior tissue formation capabilities compared to traditional products, potentially setting the stage for a first-to-market advantage in a burgeoning market. Additionally, the establishment of a U.S.-based logistics center is expected to positively impact sales of BioInk and rhCollagen, while a recent distribution agreement in Poland aims to expand the reach of its Vergenix STR product across Europe.

Bears say

CollPlant Biotechnologies Ltd has experienced challenges in achieving consistent revenue growth, as indicated by fluctuating income from its diverse product lines, including BioInk and rhCollagen. The company’s dependence on a limited number of markets, particularly the U.S. and Europe, raises concerns about its vulnerability to regional economic fluctuations and competition in the regenerative medicine sector. Additionally, the financial performance is hindered by high operational costs associated with research and development, which may affect profitability in the near term.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.